US 7,517,851 B2
	Chlamydia oligosaccharides
Cho-chou Kuo, Seattle, Wash. (US); Albertina F. Swanson, Tucson, Ariz. (US); Sen-Itiroh Hakomori, Seattle, Wash. (US); and Noriko Takahashi, Nagoya (Japan)
Assigned to The University of Washington, Seattle, Wash. (US)
Filed on Mar. 16, 2006, as Appl. No. 11/376,337.
Application 11/376337 is a division of application No. 10/732281, filed on Dec. 11, 2003, granted, now 7,053,067.
Application 10/732281 is a continuation of application No. 10/287587, filed on Nov. 05, 2002, abandoned.
Application 10/287587 is a continuation of application No. 09/230346, abandoned, previously published as PCT/US97/13037, filed on Jul. 25, 1997.
Application 09/230346 is a continuation in part of application No. 08/672849, filed on Jul. 25, 1996, abandoned.
Prior Publication US 2006/0183710 A1, Aug. 17, 2006
Int. Cl. A61K 38/38 (2006.01)

U.S. Cl. 514—8  [424/499]

76 Claims

1. A method of inhibiting binding of Chlamydia to mammalian cells comprising exposing said Chlamydia, said cells, or both, to an effective amount of a composition consisting essentially of multivalent oligosaccharide; wherein said multivalent oligosaccharide comprises a carrier linked to two or more high mannose type oligosaccharides; wherein each of said two or more high mannose type oligosaccharides comprises at least five mannose residues, and comprises a trimannosyl core consisting of at least two mannosyl branches, one branch linked α1→6 and the other branch linked α1→3 to a mannose residue and having mannosyl substitution or branching at the α1→6Man residue of the trimannosyl core.